메뉴 건너뛰기




Volumn 66, Issue 2, 2017, Pages 275-281

Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B

Author keywords

Antiviral therapy; Circular DNA; Hepatitis B virus; Liver biopsy; Virus replication

Indexed keywords

ADEFOVIR; CIRCULAR DNA; CLEVUDINE; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PREGENOMIC RNA; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ADENINE; ANTIVIRUS AGENT; NUCLEOSIDE; PHOSPHONIC ACID DERIVATIVE; THYMIDINE;

EID: 84994074820     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.08.022     Document Type: Article
Times cited : (148)

References (36)
  • 1
    • 85009986265 scopus 로고    scopus 로고
    • World Health Organization fact sheet. Hepatitis B. 2015 [cited 13 January, 2016]; Available from
    • [1] World Health Organization fact sheet. Hepatitis B. 2015 [cited 13 January, 2016]; Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
  • 2
    • 77956639159 scopus 로고    scopus 로고
    • Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
    • [2] Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
    • (2010) Hepatology , vol.52 , pp. 886-893
    • Chang, T.T.1    Liaw, Y.F.2    Wu, S.S.3    Schiff, E.4    Han, K.H.5    Lai, C.L.6
  • 3
    • 84873726484 scopus 로고    scopus 로고
    • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    • [3] Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
    • (2013) Lancet , vol.381 , pp. 468-475
    • Marcellin, P.1    Gane, E.2    Buti, M.3    Afdhal, N.4    Sievert, W.5    Jacobson, I.M.6
  • 4
    • 84872169267 scopus 로고    scopus 로고
    • Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
    • [4] Lai, C.L., Yuen, M.F., Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57 (2013), 399–408.
    • (2013) Hepatology , vol.57 , pp. 399-408
    • Lai, C.L.1    Yuen, M.F.2
  • 5
    • 0036109092 scopus 로고    scopus 로고
    • Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication
    • [5] Addison, W.R., Walters, K.A., Wong, W.W., Wilson, J.S., Madej, D., Jewell, L.D., et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76 (2002), 6356–6363.
    • (2002) J Virol , vol.76 , pp. 6356-6363
    • Addison, W.R.1    Walters, K.A.2    Wong, W.W.3    Wilson, J.S.4    Madej, D.5    Jewell, L.D.6
  • 6
    • 84940172646 scopus 로고    scopus 로고
    • HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
    • [6] Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
    • (2015) Gut , vol.64 , pp. 1972-1984
    • Nassal, M.1
  • 7
    • 84919449705 scopus 로고    scopus 로고
    • Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance
    • [7] Yang, H.C., Kao, J.H., Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect, 3, 2014, e64.
    • (2014) Emerg Microbes Infect , vol.3
    • Yang, H.C.1    Kao, J.H.2
  • 9
    • 0347635488 scopus 로고    scopus 로고
    • Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy
    • [9] Summers, J., Mason, W.S., Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 101 (2004), 638–640.
    • (2004) Proc Natl Acad Sci USA , vol.101 , pp. 638-640
    • Summers, J.1    Mason, W.S.2
  • 10
    • 33750964835 scopus 로고    scopus 로고
    • One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels
    • [10] Wong, D.K., Yuen, M.F., Ngai, V.W., Fung, J., Lai, C.L., One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 11 (2006), 909–916.
    • (2006) Antivir Ther , vol.11 , pp. 909-916
    • Wong, D.K.1    Yuen, M.F.2    Ngai, V.W.3    Fung, J.4    Lai, C.L.5
  • 11
    • 84880608443 scopus 로고    scopus 로고
    • Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency
    • [11] Wong, D.K., Seto, W.K., Fung, J., Ip, P., Huang, F.Y., Lai, C.L., et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 11 (2013), 1004–1010, e1001.
    • (2013) Clin Gastroenterol Hepatol , vol.11 , pp. 1004-1010
    • Wong, D.K.1    Seto, W.K.2    Fung, J.3    Ip, P.4    Huang, F.Y.5    Lai, C.L.6
  • 12
    • 2942532722 scopus 로고    scopus 로고
    • Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
    • [12] Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
    • (2004) Gastroenterology , vol.126 , pp. 1750-1758
    • Werle-Lapostolle, B.1    Bowden, S.2    Locarnini, S.3    Wursthorn, K.4    Petersen, J.5    Lau, G.6
  • 13
    • 84928196119 scopus 로고    scopus 로고
    • Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
    • [13] Bowden, S., Locarnini, S., Chang, T.T., Chao, Y.C., Han, K.H., Gish, R.G., et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 21 (2015), 4644–4651.
    • (2015) World J Gastroenterol , vol.21 , pp. 4644-4651
    • Bowden, S.1    Locarnini, S.2    Chang, T.T.3    Chao, Y.C.4    Han, K.H.5    Gish, R.G.6
  • 14
    • 77749308549 scopus 로고    scopus 로고
    • Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients
    • [14] Lu, H.Y., Zhuang, L.W., Yu, Y.Y., Si, C.W., Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 17 (2010), 59–65.
    • (2010) J Viral Hepat , vol.17 , pp. 59-65
    • Lu, H.Y.1    Zhuang, L.W.2    Yu, Y.Y.3    Si, C.W.4
  • 15
    • 33644818518 scopus 로고    scopus 로고
    • A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    • [15] Chang, T.T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006), 1001–1010.
    • (2006) N Engl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    de Man, R.3    Gadano, A.4    Sollano, J.5    Chao, Y.C.6
  • 16
    • 33644822860 scopus 로고    scopus 로고
    • Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B
    • [16] Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., et al. Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006), 1011–1020.
    • (2006) N Engl J Med , vol.354 , pp. 1011-1020
    • Lai, C.L.1    Shouval, D.2    Lok, A.S.3    Chang, T.T.4    Cheinquer, H.5    Goodman, Z.6
  • 17
    • 37349120537 scopus 로고    scopus 로고
    • Telbivudine vs. lamivudine in patients with chronic hepatitis B
    • [17] Lai, C.L., Gane, E., Liaw, Y.F., Hsu, C.W., Thongsawat, S., Wang, Y., et al. Telbivudine vs. lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007), 2576–2588.
    • (2007) N Engl J Med , vol.357 , pp. 2576-2588
    • Lai, C.L.1    Gane, E.2    Liaw, Y.F.3    Hsu, C.W.4    Thongsawat, S.5    Wang, Y.6
  • 18
    • 80051979890 scopus 로고    scopus 로고
    • Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
    • [18] Wong, D.K., Huang, F.Y., Lai, C.L., Poon, R.T., Seto, W.K., Fung, J., et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54 (2011), 829–836.
    • (2011) Hepatology , vol.54 , pp. 829-836
    • Wong, D.K.1    Huang, F.Y.2    Lai, C.L.3    Poon, R.T.4    Seto, W.K.5    Fung, J.6
  • 19
    • 33748939050 scopus 로고    scopus 로고
    • Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients
    • [19] Laras, A., Koskinas, J., Dimou, E., Kostamena, A., Hadziyannis, S.J., Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44 (2006), 694–702.
    • (2006) Hepatology , vol.44 , pp. 694-702
    • Laras, A.1    Koskinas, J.2    Dimou, E.3    Kostamena, A.4    Hadziyannis, S.J.5
  • 21
    • 20044374023 scopus 로고    scopus 로고
    • Design and validation of a histological scoring system for nonalcoholic fatty liver disease
    • [21] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
    • (2005) Hepatology , vol.41 , pp. 1313-1321
    • Kleiner, D.E.1    Brunt, E.M.2    Van Natta, M.3    Behling, C.4    Contos, M.J.5    Cummings, O.W.6
  • 22
    • 84875241425 scopus 로고    scopus 로고
    • Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
    • [22] Seto, W.K., Tanaka, Y., Wong, D.K., Lai, C.L., Shinkai, N., Yuen, J.C., et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 7 (2012), 98–105.
    • (2012) Hepatol Int , vol.7 , pp. 98-105
    • Seto, W.K.1    Tanaka, Y.2    Wong, D.K.3    Lai, C.L.4    Shinkai, N.5    Yuen, J.C.6
  • 23
    • 84930387219 scopus 로고    scopus 로고
    • Management of chronic hepatitis B in patients from special populations
    • [23] Lai, C.L., Yuen, M.F., Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med, 5, 2015, a021527.
    • (2015) Cold Spring Harb Perspect Med , vol.5 , pp. a021527
    • Lai, C.L.1    Yuen, M.F.2
  • 24
    • 33847410055 scopus 로고    scopus 로고
    • Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels
    • [24] Manesis, E.K., Hadziyannis, E.S., Angelopoulou, O.P., Hadziyannis, S.J., Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 12 (2007), 73–82.
    • (2007) Antivir Ther , vol.12 , pp. 73-82
    • Manesis, E.K.1    Hadziyannis, E.S.2    Angelopoulou, O.P.3    Hadziyannis, S.J.4
  • 25
    • 84880939335 scopus 로고    scopus 로고
    • Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely
    • [25] Chevaliez, S., Hezode, C., Bahrami, S., Grare, M., Pawlotsky, J.M., Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 58 (2013), 676–683.
    • (2013) J Hepatol , vol.58 , pp. 676-683
    • Chevaliez, S.1    Hezode, C.2    Bahrami, S.3    Grare, M.4    Pawlotsky, J.M.5
  • 26
    • 65449117946 scopus 로고    scopus 로고
    • Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
    • [26] Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49 (2009), 1141–1150.
    • (2009) Hepatology , vol.49 , pp. 1141-1150
    • Brunetto, M.R.1    Moriconi, F.2    Bonino, F.3    Lau, G.K.4    Farci, P.5    Yurdaydin, C.6
  • 27
    • 0027131448 scopus 로고
    • Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection
    • [27] Wu, P.C., Lau, J.Y., Lau, T.K., Lau, S.K., Lai, C.L., Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. Am J Clin Pathol 100 (1993), 648–653.
    • (1993) Am J Clin Pathol , vol.100 , pp. 648-653
    • Wu, P.C.1    Lau, J.Y.2    Lau, T.K.3    Lau, S.K.4    Lai, C.L.5
  • 28
    • 57349148151 scopus 로고    scopus 로고
    • Chronic hepatitis B–new goals, new treatment
    • [28] Lai, C.L., Yuen, M.F., Chronic hepatitis B–new goals, new treatment. N Engl J Med 359 (2008), 2488–2491.
    • (2008) N Engl J Med , vol.359 , pp. 2488-2491
    • Lai, C.L.1    Yuen, M.F.2
  • 29
    • 68349128691 scopus 로고    scopus 로고
    • The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion
    • [29] Fung, J., Lai, C.L., Tanaka, Y., Mizokami, M., Yuen, J., Wong, D.K., et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 104 (2009), 1940–1946.
    • (2009) Am J Gastroenterol , vol.104 , pp. 1940-1946
    • Fung, J.1    Lai, C.L.2    Tanaka, Y.3    Mizokami, M.4    Yuen, J.5    Wong, D.K.6
  • 30
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
    • [30] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
    • (2012) J Hepatol , vol.57 , pp. 167-185
  • 31
    • 79958800541 scopus 로고    scopus 로고
    • Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B
    • [31] Manesis, E.K., Papatheodoridis, G.V., Tiniakos, D.G., Hadziyannis, E.S., Agelopoulou, O.P., Syminelaki, T., et al. Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 55 (2011), 61–68.
    • (2011) J Hepatol , vol.55 , pp. 61-68
    • Manesis, E.K.1    Papatheodoridis, G.V.2    Tiniakos, D.G.3    Hadziyannis, E.S.4    Agelopoulou, O.P.5    Syminelaki, T.6
  • 32
    • 84883250802 scopus 로고    scopus 로고
    • High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients
    • [32] Lacombe, K., Boyd, A., Lavocat, F., Pichoud, C., Gozlan, J., Miailhes, P., et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 58 (2013), 912–922.
    • (2013) Hepatology , vol.58 , pp. 912-922
    • Lacombe, K.1    Boyd, A.2    Lavocat, F.3    Pichoud, C.4    Gozlan, J.5    Miailhes, P.6
  • 33
    • 84920983133 scopus 로고    scopus 로고
    • Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors
    • [33] van Bommel, F., Bartens, A., Mysickova, A., Hofmann, J., Kruger, D.H., Berg, T., et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61 (2015), 66–76.
    • (2015) Hepatology , vol.61 , pp. 66-76
    • van Bommel, F.1    Bartens, A.2    Mysickova, A.3    Hofmann, J.4    Kruger, D.H.5    Berg, T.6
  • 34
    • 37249092014 scopus 로고    scopus 로고
    • Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection
    • [34] Wong, D.K., Tanaka, Y., Lai, C.L., Mizokami, M., Fung, J., Yuen, M.F., Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 45 (2007), 3942–3947.
    • (2007) J Clin Microbiol , vol.45 , pp. 3942-3947
    • Wong, D.K.1    Tanaka, Y.2    Lai, C.L.3    Mizokami, M.4    Fung, J.5    Yuen, M.F.6
  • 35
    • 84879458710 scopus 로고    scopus 로고
    • Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation
    • [35] Matsuzaki, T., Tatsuki, I., Otani, M., Akiyama, M., Ozawa, E., Miuma, S., et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol 28 (2013), 1217–1222.
    • (2013) J Gastroenterol Hepatol , vol.28 , pp. 1217-1222
    • Matsuzaki, T.1    Tatsuki, I.2    Otani, M.3    Akiyama, M.4    Ozawa, E.5    Miuma, S.6
  • 36
    • 84962605530 scopus 로고    scopus 로고
    • Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma
    • [36] Honda, M., Shirasaki, T., Terashima, T., Kawaguchi, K., Nakamura, M., Oishi, N., et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 213 (2016), 1096–1106.
    • (2016) J Infect Dis , vol.213 , pp. 1096-1106
    • Honda, M.1    Shirasaki, T.2    Terashima, T.3    Kawaguchi, K.4    Nakamura, M.5    Oishi, N.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.